FadiTazaMD

Hematologic Oncology

Hematology and Oncology Fellow at Indiana University

Dr. Taza is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1400 N Ritter Ave Ste 340
Indianapolis, IN 46219
Phone+1 317-355-5870

Dr. Fadi Taza is an oncologist in Indianapolis, IN. Dr. taza received Dr. Tazas medical degree from Damascus University Faculty of Medicine and has been in practice 3 years. Dr. taza specializes in hematologic oncology. Dr. taza has more than 10 publications and over 100 citings.

PubMed

64 citations
Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.
Costantine Albany, Nabil Adra, Anna C. Snavely, Clint Cary, Timothy A. Masterson
Annals of Oncology. 2018-02-01
29 citations
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer
Fadi Taza, Albert E Holler, Wei Fu, Hao Wang, Nabil Adra
JCO Precision Oncology. 2021-07-22
32 citations
Takotsubo cardiomyopathy triggered by SARS-CoV-2 infection in a critically ill patient.
Fadi Taza, Mary Zulty, Arjun Kanwal, Daniel Grove
BMJ Case Reports. 2020-06-01

Abstracts/Posters

Salvage high-dose chemotherapy (HDCT) for relapsed primary mediastinal nonseminomatous germ-cell tumors (PMNSGCT)
Taza F, Abonour R, Althouse S, Ashkar R, Abu Zaid M, Hanna N, Kessler K, Adra N, Einhorn L., 2022 ASCO Annual Meeting - Chicago, Illinois
Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer
Taza F, Holler AE, Adra N, Ashkar R, Sokolova AO, Kessel A, Nafissi N, Barata P, Bastos D, Smaletz O, Berchuck JE, Aggarwal R, Vlachostergios PJ, Su C, Marshall CH, An..., 2021 GU ASCO Annual Meeting- San Francisco, California
The prognostic value of teratoma in the primary tumor and postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specimens in patients with germ cell tumors...
Taza F, Chovanec M, Snavely A, Adra N, Hanna N, Cary C, Masterson T, Einhorn L, Albany C., 2018 ASCO Annual Meeting- Chicago, IL
Retroperitoneal cancer viability after postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in good risk germ cell tumors (GCTs)
Taza F, Chovanec M, Snavely A, Adra N, Hanna N, Cary C, Masterson T, Einhorn L, Albany C, 2018 ASCO Annual Meeting- Chicago, IL
Causes and patterns of mortality in patients with lethal germ cell tumor (GCT).
Hamid A, Funt S.A, Markt S.C, Bromberg M, O'Donnell D, Adra N, Taza F, Albany C, Krailo M.D, Frazier L, Einhorn L, Feldman D.R, Sweeney C, 2020 GU ASCO Annual Meeting- San Francisco, CA.
Join now to see all

Lectures

Retroperitoneal cancer viability after postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in good risk germ cell tumors (GCTs).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
The prognostic value of teratoma in the primary tumor and postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specimens in patients with germ cell tumors...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018